397 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author최한곤-
dc.date.accessioned2018-08-31T08:06:14Z-
dc.date.available2018-08-31T08:06:14Z-
dc.date.issued2009-03-
dc.identifier.citationVASCULAR PHARMACOLOGY, v. 50, No. 3-4, Page. 123-131en_US
dc.identifier.issn1537-1891-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1537189108001432-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/74703-
dc.description.abstractAngiogenesis plays a critical role in the pathogenesis of malignant tumor growth and metastases. Since cyclooxygenase (COX)-2 expression is positively correlated with vascular endothelial growth factor (VEGF) expression and enhanced angiogenesis, COX-2 inhibitors have been focused on as angiogenesis-inhibiting drugs that may offer a complementary modality to classical strategies for cancer therapy. In this study, we evaluated the potential antiangiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3), a dual COX/5-LOX inhibitor. In HT1080 cancer cells, FPP-3 significantly suppressed release of VEGF as well as activation of NF-kappa B. a transcriptional factor required for VEGF expression. In a chick chorioallantoic membrane (CAM) assay, FPP-3 dose-dependently suppressed VEGF- and MCF-7 human breast cancer cell-induced angiogenesis. In experiments with human umbilical vein endothelial cells (HUVECs), FPP-3 dose-dependently decreased not only the cell survival and proliferation but also the tube formation and invasion using Matrigel-coated plates. Such antiangiogenic activity correlated with suppression of VEGF-induced matrix metalloproteinase (MMP)-2 expression, reactive oxygen species (ROS) production, and extracellularly regulated kinase (ERK) phosphorylation. Furthermore, in contrast to the case of NS398, a selective COX-2 inhibitor, FPP-3 did not alter the ratio of tissue factor (TF)/tissue factor pathway inhibitor (TFPI) expression, a coagulation index. These results indicate that FPP-3 could be used as an effective antiangiogenic agent without the risk of developing thrombotic complications. (c) 2008 Elsevier Inc. All rights reserved.en_US
dc.description.sponsorshipThis work was supported by grant no. RT104-01-04, from the Regional Technology Innovation Program of the Ministry of Commerce, Industry, and Energy (MOCIE).en_US
dc.language.isoen_USen_US
dc.publisherELSEVIER SCIENCE INCen_US
dc.subjectPropenoneen_US
dc.subjectCOX-2en_US
dc.subjectTumor angiogenesisen_US
dc.subjectROSen_US
dc.subjectpERKen_US
dc.subjectTissue factoren_US
dc.titleThe anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signalingen_US
dc.typeArticleen_US
dc.relation.no3-4-
dc.relation.volume50-
dc.identifier.doi10.1016/j.vph.2008.11.006-
dc.relation.page123-131-
dc.relation.journalVASCULAR PHARMACOLOGY-
dc.contributor.googleauthorPark, Byung Chul-
dc.contributor.googleauthorPark, Su-Young-
dc.contributor.googleauthorLee, Jong-Suk-
dc.contributor.googleauthorMousa, Shaker A-
dc.contributor.googleauthorKim, Jong Tae-
dc.contributor.googleauthorKwak, Mi-Kyoung-
dc.contributor.googleauthorKang, Keon Wook-
dc.contributor.googleauthorLee, Eung-Seok-
dc.contributor.googleauthorChoi, Han Gon-
dc.contributor.googleauthorYong, Chul Soon-
dc.contributor.googleauthorKim, Jung-Ae-
dc.relation.code2009214177-
dc.sector.campusE-
dc.sector.daehakCOLLEGE OF PHARMACY[E]-
dc.sector.departmentDEPARTMENT OF PHARMACY-
dc.identifier.pidhangon-
Appears in Collections:
COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE